Replimune director receives 44,500 share options

Replimune Group, Inc. director Paolo Pucci received a grant of stock options covering 44,500 shares of Common Stock.

Rhea-AI Filing Summary

Replimune Group, Inc. director Paolo Pucci received a grant of stock options covering 44,500 shares of Common Stock. The options have a per-share exercise price of $7.61 and expire on April 1, 2036. All underlying shares vest in a single tranche on April 1, 2027. This is a compensation-related award rather than an open-market purchase or sale, and after this grant Pucci holds 44,500 stock options directly.

Insider Trade Summary

Grant/Award: 44,500 shares

Grant/Award 1 txn

Insider Pucci Paolo

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	44,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 44,500 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option vest entirely on April 1, 2027.

Key Figures

Option grant size: 44,500 shares Exercise price: $7.61 per share Total options after grant: 44,500 options +2 more

5 metrics

Option grant size 44,500 shares Stock Option (right to buy) granted to director

Exercise price $7.61 per share Conversion or exercise price of stock options

Total options after grant 44,500 options Total derivative securities following transaction

Vesting date April 1, 2027 All underlying shares vest on this date

Expiration date April 1, 2036 Option expiration date

Key Terms

Stock Option (right to buy), Common Stock, vesting, Form 4

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"The shares underlying this option vest entirely on April 1, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Replimune (REPL) director Paolo Pucci report in this Form 4?

Paolo Pucci reported receiving a grant of stock options for 44,500 shares of Replimune Common Stock. These options are a compensation-related award, not an open-market trade, and give him the right to buy shares at a fixed exercise price.

How many Replimune (REPL) shares are covered by Pucci’s new stock options?

The grant covers options on 44,500 shares of Replimune Common Stock. This entire amount was awarded in a single transaction and represents Pucci’s reported option holdings following the transaction in this Form 4 filing.

What is the exercise price of Paolo Pucci’s Replimune (REPL) stock options?

The options have an exercise price of $7.61 per share. This means Pucci can choose to buy Replimune Common Stock at $7.61 under the terms of the option grant, once the options have vested and before they expire.

When do Paolo Pucci’s Replimune (REPL) stock options vest and expire?

All 44,500 option shares vest on April 1, 2027, according to the filing footnote. The options expire on April 1, 2036, giving Pucci a long window to exercise them after vesting, subject to applicable plan and agreement terms.

Is this Replimune (REPL) Form 4 a stock buy or sell by Paolo Pucci?

The filing reflects a grant of stock options, not a market buy or sell. The transaction is coded as an acquisition related to a grant or award, indicating compensation rather than an open-market purchase or sale of Replimune shares.

How many Replimune (REPL) options does Paolo Pucci hold after this grant?

After the reported transaction, Pucci directly holds stock options covering 44,500 shares. The Form 4 shows this as his total derivative holdings following the grant, with no additional remaining derivative positions listed in the derivative summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/07/2026 - 09:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pucci Paolo

(Last) (First) (Middle)

C/O REPLIMUNE GROUP, INC.

500 UNICORN PARK DRIVE, SUITE 303

(Street)

WOBURN MASSACHUSETTS 01801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.61	04/01/2026		A		44,500		(1)	04/01/2036	Common Stock	44,500	$0	44,500	D

Explanation of Responses:

1. The shares underlying this option vest entirely on April 1, 2027.

Remarks:

This Form 4 is being filed late due to inadvertent administrative error.

	/s/ Shawn Glidden, attorney-in-fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)